FANG Xiang-hua. The Use and Limitation of Surrogate End Points in the Cardiovascular Diseases Clinical Trials[J]. Journal of Evidence-Based Medicine, 2005, 5(6): 364-367. DOI: 10.3969/j.issn.1671-5144.2005.06.013
|
Citation:
|
FANG Xiang-hua. The Use and Limitation of Surrogate End Points in the Cardiovascular Diseases Clinical Trials[J]. Journal of Evidence-Based Medicine, 2005, 5(6): 364-367. DOI: 10.3969/j.issn.1671-5144.2005.06.013
|
FANG Xiang-hua. The Use and Limitation of Surrogate End Points in the Cardiovascular Diseases Clinical Trials[J]. Journal of Evidence-Based Medicine, 2005, 5(6): 364-367. DOI: 10.3969/j.issn.1671-5144.2005.06.013
|
Citation:
|
FANG Xiang-hua. The Use and Limitation of Surrogate End Points in the Cardiovascular Diseases Clinical Trials[J]. Journal of Evidence-Based Medicine, 2005, 5(6): 364-367. DOI: 10.3969/j.issn.1671-5144.2005.06.013
|
DownLoad: